Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
暂无分享,去创建一个
Ralph Weissleder | Miyoung Chun | Umar Mahmood | Timothy Ocain | Elena S Izmailova | Herlen Alencar | Miyoung Chun | R. Weissleder | U. Mahmood | M. Hepperle | B. Jaffee | T. Ocain | Yajun Xu | Herlen Alencar | N. Paz | E. Izmailova | Geraldine Harriman | Yajun Xu | G. Harriman | Nancy Paz | Lisa Schopf | Michael Hepperle | Joan H Lane | Aileen M Healy | Bruce Jaffee | L. Schopf | A. Healy | J. Lane | Mckenna Lane
[1] A. Baldwin,et al. THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .
[2] P. Tak,et al. NF-κB: a key role in inflammatory diseases , 2001 .
[3] R. Weissleder,et al. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. , 2004, Arthritis and rheumatism.
[4] H. Carlsen,et al. In Vivo Imaging of NF-κB Activity1 , 2002, The Journal of Immunology.
[5] M. Karin,et al. Missing Pieces in the NF-κB Puzzle , 2002, Cell.
[6] M J May,et al. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.
[7] A. Manning,et al. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. , 1998, Autoimmunity.
[8] P. Riel,et al. Uncoupling of inflammation and destruction in rheumatoid arthritis : Myth or reality? , 2005 .
[9] R N Maini,et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. , 2005, Arthritis and rheumatism.
[10] James F. Callahan,et al. Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation , 2005, Journal of Pharmacology and Experimental Therapeutics.
[11] C. Brinckerhoff,et al. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? , 2002, Arthritis and rheumatism.
[12] B. Bresnihan,et al. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. , 2000, Arthritis and rheumatism.
[13] K. McIntyre,et al. Reduced incidence and severity of collagen‐induced arthritis in interleukin‐12‐deficient mice , 1996, European journal of immunology.
[14] G. Vaes,et al. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. , 1977, The Biochemical journal.
[15] R. Gay,et al. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. , 2010, Arthritis and rheumatism.
[16] W. English,et al. Matrix metalloproteinases in arthritic disease , 2002, Arthritis research.
[17] B. Bresnihan. Pathogenesis of joint damage in rheumatoid arthritis. , 1999, The Journal of rheumatology.
[18] Maciewicz Ra,et al. Degradation of cartilage matrix components by the cysteine proteinases, cathepsins B and L. , 1991 .
[19] L. Devi,et al. Inflammatory Mediators Regulate Cathepsin S in Macrophages and Microglia: A Role in Attenuating Heparan Sulfate Interactions , 1999, Molecular medicine.
[20] B. Bresnihan,et al. Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. , 2004, Arthritis and rheumatism.
[21] M. Silva,et al. IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis , 2006 .
[22] V. Sasseville,et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. , 2006, Blood.
[23] P. Petrow,et al. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium. , 2000, The Journal of rheumatology.
[24] C. Bever,et al. Effect of protein kinase modulators on the regulation of cathepsin B activity in THP-1 human monocytic leukemia cells. , 1998, Oncology reports.
[25] H. Pahl. Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.
[26] R. Weissleder,et al. Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[27] B. Bresnihan,et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. , 2001, Arthritis & Rheumatism.